Join
Live feed
·
PRReleasevia Quantisnow
Tyra Biosciences Inc. logo

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

ByQuantisnow·Wall Street's wire, on your screen.
TYRA· Tyra Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TYRA (Tyra Biosciences Inc.) and more on Quantisnow.